Exec Chat: Abbott Invests In Outreach To Underrepresented Populations
Executive Summary
Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott’s vascular device business, talked to Medtech Insight about her company’s ongoing efforts to diversify patient enrollment in clinical trials by communicating more effectively and compassionately with people in traditionally underrepresented demographic groups.
You may also be interested in...
How Can Pharma Seek To Discuss Gender Diversity?
As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.
FDA Draft Guidance Takes Aim At Racial, Ethnic Disparities In Clinical Trials
The US agency has outlined steps industry can take to ensure clinical trials include a broader representation of underrepresented racial and ethnic groups.
Abbott Focuses On Improving Early Diagnosis Of Vascular Disease To Improve Outcomes
Nick West, chief medical officer for Abbott’s vascular business talked to Medtech Insight about Abbott’s efforts to improve the assessment and treatment of vascular disease long before patients need an intervention.